Is TRT Safe? The Evidence Explained

For decades, testosterone replacement therapy carried a cloud of concern that outpaced the evidence. Headlines in the 2010s linked TRT to heart attacks. Older guidelines warned about prostate cancer. Patients walked into clinics already convinced that treating their symptoms would cost them their health. Most of that fear is no longer supported by the current data.

This post walks through what the best available research actually shows about TRT safety: the cardiovascular data from the TRAVERSE trial, the prostate cancer evidence, the real side effects men should know about, and the situations where TRT genuinely is not appropriate. The goal is to give you the nuanced picture clinicians use when deciding whether TRT is right for a specific patient.

Why the TRT Safety Debate Changed in 2023

The turning point in the TRT safety conversation was the TRAVERSE trial published in the New England Journal of Medicine in June 2023. This was a prospective, randomized, double-blind, placebo-controlled study of 5,204 middle-aged and older men with hypogonadism and existing cardiovascular disease or high cardiovascular risk. Men were assigned to receive either testosterone gel or placebo gel, and followed for a median of 22 months.

The primary endpoint was major adverse cardiac events (MACE): cardiovascular death, non-fatal heart attack, or non-fatal stroke. The result: TRT did not increase cardiovascular events compared to placebo. This is the largest, most rigorous TRT safety trial ever conducted, and it effectively closed the “does TRT cause heart attacks” question that had been open for more than a decade.

The reason this question was ever open traces back to a small handful of flawed retrospective studies published between 2010 and 2014 that suggested cardiovascular harm. Those studies had major methodological problems: one used VA data where men who had strokes were coded as not having received TRT, another compared TRT users to men with lower cardiovascular risk at baseline, and neither was prospective. The FDA required a boxed warning on TRT products based on these studies, which drove much of the public fear. TRAVERSE was designed specifically to answer the question with adequate rigor, and it did.

Is TRT Safe for the Prostate?

This is the other fear most men bring to a TRT consultation. The longstanding worry came from a 1941 paper by Charles Huggins showing that lowering testosterone treats metastatic prostate cancer. The flawed inference drawn from that was: if lower testosterone treats cancer, higher testosterone must cause cancer. This turned out to be wrong.

Prostate tissue has androgen receptors that saturate at relatively low testosterone levels. Once saturated, adding more testosterone does not further stimulate prostate tissue growth. This is why men with genuinely low testosterone can restore levels to normal without triggering prostate cancer.

Meta-analyses of TRT trials and long-term registry data consistently show no increase in prostate cancer incidence among men on TRT compared to matched controls. TRAVERSE also tracked prostate cancer incidence and found no significant increase.

The nuance: men with existing, untreated prostate cancer should not start TRT. Men with a history of treated prostate cancer require careful urological consultation before starting TRT. For the general hypogonadal male without a prostate cancer history, the prostate cancer concern has been substantially overstated.

The Real Side Effects of TRT

TRT has genuine side effects that are worth understanding. These are manageable and generally predictable, but they do require monitoring.

Erythrocytosis (Increased Red Blood Cells)

Testosterone stimulates red blood cell production. On TRT, hematocrit typically rises. For most men, this is a benefit: hematocrit that was low or low-normal moves into a healthier range. For some men, hematocrit rises above 52% (the typical upper limit), which requires attention.

Management options include reducing dose, switching from injections to transdermal or oral forms (which raise hematocrit less), or therapeutic phlebotomy (essentially a blood donation) to bring hematocrit down. Monitoring hematocrit every 3 to 6 months on TRT is standard, per the Endocrine Society Clinical Practice Guideline.

Acne and Oily Skin

Some men develop acne on TRT, particularly on the back and chest. This is usually mild and resolves with dose adjustment or topical treatment. It is more common in men prone to acne before treatment.

Fluid Retention

Mild water retention is common in the first weeks of TRT and usually resolves as the body adapts. Men with heart failure or kidney disease require more careful monitoring because fluid retention can worsen those conditions.

Testicular Shrinkage and Infertility

This is the side effect that concerns younger men most. External testosterone signals the brain to stop producing luteinizing hormone (LH), which is what normally tells the testes to make testosterone and sperm. Without LH signaling, the testes shrink and sperm production decreases. In some men sperm production stops entirely.

The good news: this is manageable and often reversible. HCG (human chorionic gonadotropin) mimics LH and can maintain testicular function during TRT. Men planning to have children can often preserve fertility by adding HCG to their protocol. Our full post on HCG on TRT explains how this works.

Mood and Sleep Changes

Most men feel better on TRT. A small minority experience increased irritability, anxiety, or sleep disruption, particularly in the first few weeks or at high doses. These usually resolve with dose adjustment.

Estrogen-Related Side Effects

Testosterone converts to estradiol via the aromatase enzyme. Some men on TRT develop elevated estradiol, which can cause water retention, nipple sensitivity, mood issues, or gynecomastia in extreme cases. This is managed through dose adjustment, body composition changes, or selective use of an aromatase inhibitor. See our post on high estrogen symptoms on TRT for specifics.

Who Should Not Start TRT?

TRT is not appropriate for everyone. The following are contraindications or reasons for caution.

• Active prostate cancer or breast cancer: absolute contraindication
• Uncontrolled heart failure: TRT can worsen fluid retention
• Hematocrit above 52% at baseline: TRT will make this worse without aggressive management
• Untreated severe sleep apnea: TRT can worsen sleep apnea, and untreated sleep apnea limits TRT benefits
• Men actively trying to conceive: TRT suppresses sperm production; enclomiphene or HCG are better first-line options
• Unexplained elevated PSA or prostate nodule: requires urological workup before TRT
• Pregnancy of partner (gel formulations): transfer risk; alternative formulations needed

These are not permanent disqualifications in most cases. A sleep apnea diagnosis that is treated makes TRT reasonable. A resolved cancer with appropriate urology clearance makes TRT reasonable. The point is that every TRT decision is individualized to the patient’s medical history.

How Tactus Health Approaches TRT Safety

Dr. Ashar’s approach to TRT safety is grounded in three principles. First, comprehensive baseline evaluation before prescribing. This includes full labs (testosterone total and free, estradiol, PSA, lipids, metabolic panel, CBC), medical history, medication review, and sleep screening. Second, individualized dosing with specific attention to keeping levels in a physiologic range, not supraphysiologic. Third, structured follow-up with labs at 6 weeks, 3 months, and then every 6 to 12 months once stable.

The Endocrine Society guideline and the TRAVERSE trial both support this approach. Men who are appropriately evaluated, appropriately dosed, and monitored consistently have excellent outcomes on TRT with very low rates of serious adverse events.

TRT Safety Summary

The accumulated evidence on modern TRT, summarized briefly, looks like this:

• Cardiovascular safety: TRAVERSE closed the heart attack question. No increased risk of major cardiac events versus placebo in men with hypogonadism.
• Prostate cancer: Not caused by TRT in men without pre-existing disease. Standard PSA monitoring on treatment is sufficient for most men.
• Real side effects: Erythrocytosis, acne, fluid retention, testicular suppression, and estradiol changes. All manageable.
• Contraindications: Active hormone-sensitive cancer, uncontrolled heart failure, baseline erythrocytosis, untreated sleep apnea, active conception attempts.
• The real question: Not “is TRT safe” in the abstract, but whether the benefits for your specific situation outweigh the manageable risks.

Medically Reviewed By

Dr. Ashar N., DNP, APRN, FNP-C, PMHNP-BC

Co-Founder & Medical Director at Tactus Health. Dual board-certified, with clinical focus on testosterone therapy, hormone optimization, and metabolic health. In-person care in Sugar Hill, GA, and telehealth TRT for Georgia residents.